IMBRUVICA™ (Ibrutinib) Now Approved in the u.s. For Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
HORSHAM, PA, February 12, 2014 – Janssen Biotech, Inc. [“Janssen”] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™…